This ICare4Autism and Albert Einstein College of Medicine presentation was Co-Sponsored by Shema Kolainu- Hear Our Voices School and Center for Children, Montefiore the University Hospital for Albert Einstein College of Medicine, and Coronado Biosciences.
We thank all of our sponsors and exhibitors for their commitment towards making this conference a reality and success.
With special thanks to Albert Einstein College of Medicine for hosting the event and to Shema Kolainu – Hear Our Voices, School and Center for Children with Autism.
|Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company’s two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis, multiple sclerosis, psoriasis, type 1 diabetes and autism; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumors.|
|BioAdvantex Pharma manufactures PharmaNAC effervescent N-actetylcysteine tablets supplied to a study in children with autism conducted by Stanford University. Published in the June 2012 issue of Biological Psychiatry, the study reports that children taking doses up to 3 tablets of PharmaNAC daily, containing 2700mg of n-acetylcysteine had improvements in irritability and repetitive behavior.|
|The Sluis Academy is a wholly Canadian owned company that offers a unique program of adaptive physical education in conjunction with development of social skills in persons with special needs, most specifically, with those persons exhibiting symptoms of autism and fetal alcohol syndrome.|